These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 24448177

  • 1. Honokiol nanosuspensions: preparation, increased oral bioavailability and dramatically enhanced biodistribution in the cardio-cerebro-vascular system.
    Han M, Yu X, Guo Y, Wang Y, Kuang H, Wang X.
    Colloids Surf B Biointerfaces; 2014 Apr 01; 116():114-20. PubMed ID: 24448177
    [Abstract] [Full Text] [Related]

  • 2. Preparation of honokiol nanoparticles by liquid antisolvent precipitation technique, characterization, pharmacokinetics, and evaluation of inhibitory effect on HepG2 cells.
    Wu W, Wang L, Wang L, Zu Y, Wang S, Liu P, Zhao X.
    Int J Nanomedicine; 2018 Apr 01; 13():5469-5483. PubMed ID: 30271141
    [Abstract] [Full Text] [Related]

  • 3. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
    Zhang X, Zhang T, Lan Y, Wu B, Shi Z.
    AAPS PharmSciTech; 2016 Apr 01; 17(2):400-8. PubMed ID: 26187778
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol.
    Wang XH, Cai LL, Zhang XY, Deng LY, Zheng H, Deng CY, Wen JL, Zhao X, Wei YQ, Chen LJ.
    Int J Pharm; 2011 May 30; 410(1-2):169-74. PubMed ID: 21397675
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C, Dang Y, Lin G, Yao Y, Li G, Ji G, Shen H, Xie Y.
    Int J Pharm; 2014 Dec 30; 477(1-2):251-60. PubMed ID: 25445518
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide.
    Sahu BP, Das MK.
    Acta Pol Pharm; 2014 Dec 30; 71(1):129-37. PubMed ID: 24779201
    [Abstract] [Full Text] [Related]

  • 15. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
    Sawant KK, Patel MH, Patel K.
    Drug Dev Ind Pharm; 2016 Dec 30; 42(5):758-68. PubMed ID: 26548349
    [Abstract] [Full Text] [Related]

  • 16. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S, Reddy VA, Arora S, Patel K.
    Drug Deliv Transl Res; 2016 Oct 30; 6(5):498-510. PubMed ID: 27129488
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Honokiol/Magnolol-Loaded Self-Assembling Lecithin-Based Mixed Polymeric Micelles (lbMPMs) for Improving Solubility to Enhance Oral Bioavailability.
    Lin HL, Cheng WT, Chen LC, Ho HO, Lin SY, Hsieh CM.
    Int J Nanomedicine; 2021 Oct 30; 16():651-665. PubMed ID: 33536753
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.